SCHEMBL5451781

SCHEMBL5451781

CCOC(=O)c1cccc(-c2ccc(CC3SC(=O)NC3=O)o2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.54
POLB P06746 2/20 0.54
TP53 P04637 1/20 0.54
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
CYP2C9 P11712 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
PIK3CG P48736 1/20 0.43
KMT2A Q03164 2/20 0.41
PTGES O14684 1/20 0.41
MEN1 O00255 1/20 0.41
HIF1A Q16665 1/20 0.41
MPC2 O95563 1/20 0.41
CYP2C8 P10632 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447795 0.89 MAPT (0.60) HPGDPOLBTP53MAPTALDH1A1
SCHEMBL5167894 0.85 PIK3CG (0.50) POLBMAPTALDH1A1KDM4ECYP2C9
SCHEMBL5451828 0.82 FFAR1 (0.49) HPGDPOLBTP53MAPTALDH1A1
SCHEMBL12990407 0.82 PIK3CG (0.49) HPGDPOLBTP53MAPTALDH1A1
SCHEMBL5167121 0.79 KCNH2 (0.49) HPGDMAPTALDH1A1KDM4ENPC1
SCHEMBL5169080 0.79 PPARG (0.49) POLBMAPTALDH1A1KDM4ECYP2C9
SCHEMBL5168227 0.78 RXRA (0.49) ALDH1A1KDM4ERAB9ACYP1A2CYP2C19
SCHEMBL5167984 0.77 FFAR1 (0.48) MAPTALDH1A1KDM4ECYP2C9MPC2
SCHEMBL15356751 0.72 FFAR1 (0.49) HPGDTP53MAPTALDH1A1KDM4E
SCHEMBL3055510 0.71 HPGD (0.66) HPGDPOLBTP53MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US claimed
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'OREAL (FR) 2007-04-05 US claimed
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US disclosed
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US disclosed
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US disclosed
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'OREAL (FR) 2007-04-05 US disclosed
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'OREAL (FR) 2007-04-05 US disclosed
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'OREAL (FR) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening TYR, KRT18, MITF HPGD 120/4885POLB 1022/4885TP53 1718/4885
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof KRT18, NGF, FGF1 HPGD 1667/4885POLB 1985/4885TP53 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.